Innovative male circumcision device for HIV prevention receives WHO prequalification

June 24, 2015

June 24, 2015 -- Washington, DC -- The ShangRing, a novel medical device for voluntary medical male circumcision, has received prequalification from the World Health Organization (WHO) for use. The prequalification indicates that the ShangRing meets international standards of safety and has the potential to rapidly increase access to the device in sub-Saharan Africa and other regions where the burden of HIV is highest. Conclusive clinical research demonstrates that circumcision can reduce male acquisition of HIV through vaginal intercourse by up to 60 percent.

"This is a major milestone toward improving access to voluntary medical male circumcision, which will help to prevent HIV acquisition in low-resource settings and contribute to the international efforts to achieve an AIDS-free generation," said Mr. Shang Jianzhong, inventor and board chairman of Wuhu Snnda Medical Treatment Appliance Technology Co., Ltd.

In 2007, WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) recommended that voluntary medical male circumcision be included in HIV prevention programs in southern and eastern Africa, countries with high rates of heterosexually transmitted HIV and low rates of male circumcision. While WHO prequalification does not replace national regulatory approvals, it acts as a guide for many national health agencies and enables procurement of the device by programs such as the United States President's Emergency Plan for AIDS Relief (PEPFAR).

The ShangRing is produced by Wuhu Snnda Medical Treatment Appliance Technology Co., Ltd of China. It consists of two concentric plastic rings that lock together over the foreskin. Unlike the conventional surgery, male circumcision with the ShangRing requires no sutures, involves minimal bleeding and is disposable. It is the first device prequalified by WHO for circumcision of both adults and adolescent boys ages 13 to 17 years.

"The ShangRing is very simple to use and reduces the time needed to perform male circumcision by about half, compared to conventional procedures," says Jairus Oketch, Kenya Registered Community Health Nurse, Homa Bay District Hospital. "Expanded use of the device will enable countries to deliver safe, efficient, high-quality male circumcision to more people and thus reduce the spread of HIV."

The ShangRing was assessed among more than 1,900 healthy adult men ages 18 years and older in five studies conducted in Kenya, Uganda and Zambia and among more than 350 adolescent males ages 13 to 17 years in Kenya and Uganda. The research in Kenya and Zambia was supported by a grant from the Bill & Melinda Gates Foundation to FHI 360 and conducted in collaboration with EngenderHealth, FHI 360 and Weill Cornell Medical College. The partners were instrumental in clinical research, provider training, inspection of the manufacturing facility and coordination with WHO.
-end-
About Wuhu Snnda Medical Treatment Appliance Technology Co., Ltd.

Wuhu Snnda Medical Treatment Appliance Technology Co., Ltd., is a cooperatively managed enterprise that manufactures Class II medical devices in accordance with the level of medical products classification. It was founded in June 2006 and is located in the Wuhu State-level Economic & Technological Development Zone. Visit http://www.snnda.com for additional information.

About EngenderHealth

EngenderHealth is a leading global women's health organization committed to ensuring that every pregnancy is planned, every child is wanted, and every mother has the best chance at survival. In 20 countries around the world, we train health care professionals and partner with governments and communities to make high-quality family planning and sexual and reproductive health services available--today and for generations to come. Visit http://www.engenderhealth.org for more information.

About FHI 360

FHI 360 is a nonprofit human development organization dedicated to improving lives in lasting ways by advancing integrated, locally driven solutions. Our staff includes experts in health, education, nutrition, environment, economic development, civil society, gender, youth, research, technology, communication and social marketing -- creating a unique mix of capabilities to address today's interrelated development challenges. FHI 360 serves more than 70 countries and all U.S. states and territories. For more information, visit fhi360.org.

About Weill Cornell Medical College

Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.

Media Contacts:

Engender Health
Theresa Kim
tkim@engenderhealth.org
Tel: 646.808.6446

FHI 360
Natasha Abel
nabel@fhi360.org
Tel: 202.884.8018

Weill Cornell Medical College
Sarah Smith
sas2072@med.cornell.edu
646.317.7401

Weill Cornell Medicine

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.